1. Home >
  2. M&A >
  3. Divestiture >
  4. United States >
  5. Maryland >
  6. Lupin Acquires Lupin s U.S. Commercial Women s Health Specialty Business

M&A Deal Summary

Lupin Acquires Lupin s U.S. Commercial Women s Health Specialty Business

On July 15, 2024, Lupin acquired life science company Lupin s U.S. Commercial Women s Health Specialty Business from Lupin

Acquisition Highlights
  • This is Lupin’s 8th transaction in the Life Science sector.
  • This is Lupin’s 4th transaction in the United States.
  • This is Lupin’s 1st transaction in Maryland.

M&A Deal Summary
Date 2024-07-15
Target Lupin s U.S. Commercial Women s Health Specialty Business
Sector Life Science
Buyer(s) Lupin
Sellers(s) Lupin
Deal Type Divestiture

Target

Lupin s U.S. Commercial Women s Health Specialty Business

Baltimore, Maryland, United States
Lupin's U.S. Commercial Women's Health Specialty Business is focused on commercializing SOLOSEC (secnidazole) 2g oral granules. It is an FDA-approved single-dose antimicrobial agent that provides a complete course of therapy for the treatment of bacterial vaginosis (BV) and trichomoniasis, two common sexual health infections.

Search 214,238 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Lupin

Mumbai, India
Category Company
Founded 1968
Sector Life Science
Employees24,006
Revenue 221.9B INR (2025)
DESCRIPTION

Lupin is an innovation-led transnational pharmaceutical company producing and developing a wide range of branded & generic formulations, APIs and biotechnology products. Lupin was founded in 1968 and is based in Mumbai, Maharashtra.

DEAL STATS #
Overall 9 of 11
Sector: Life Science M&A 8 of 9
Type: Divestiture M&A Deals 2 of 3
State: Maryland M&A 1 of 1
Country: United States M&A 4 of 5
Year: 2024 M&A 1 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2019-11-11 Kyowa Pharmaceutical

Osaka, Japan

Kyowa Pharmaceutical is a generic pharmaceutical company and is the domestic provider in the Central Nervous System (CNS) therapeutic area. Kyowa Pharmaceutical was founded in 1954 and is based in Osaka, Japan.

Sell -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2024-12-30 Eli Lilly - Huminsulin

Indianapolis, Indiana, United States

Eli Lilly's Huminsulin range of products is indicated for the treatment of type 1 and type 2 diabetes mellitus to improve blood sugar control in both adults and children.

Buy -

Seller(S) 1

SELLER

Lupin

Mumbai, India
Category Company
Founded 1968
Sector Life Science
Employees24,006
Revenue 221.9B INR (2025)
DESCRIPTION

Lupin is an innovation-led transnational pharmaceutical company producing and developing a wide range of branded & generic formulations, APIs and biotechnology products. Lupin was founded in 1968 and is based in Mumbai, Maharashtra.

DEAL STATS #
Overall 2 of 2
Sector: Life Science M&A 2 of 2
Type: Divestiture M&A Deals 1 of 1
State: Maryland M&A 1 of 1
Country: United States M&A 1 of 1
Year: 2024 M&A 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2019-11-11 Kyowa Pharmaceutical

Osaka, Japan

Kyowa Pharmaceutical is a generic pharmaceutical company and is the domestic provider in the Central Nervous System (CNS) therapeutic area. Kyowa Pharmaceutical was founded in 1954 and is based in Osaka, Japan.

Sell -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2024-12-30 Eli Lilly - Huminsulin

Indianapolis, Indiana, United States

Eli Lilly's Huminsulin range of products is indicated for the treatment of type 1 and type 2 diabetes mellitus to improve blood sugar control in both adults and children.

Buy -
Mergr

Solution for

Product

Company

Legal